fireflyneuro.com (AIFF) - Price-to-Projected Revenue Ratio
High costs for FDA certification and patent protection of AI platforms are impacting the growth dynamics of Firefly Neuroscience, Inc (AIFF). The forward P/S ratio reflects the current market capitalization relative to future revenues, with the metric fixed at 7.40. Brand authority among neurologists is increasing due to precise EEG decoding, while unique dementia diagnostic software provides the company with sustainable pricing power within the niche.
Comprehensive metric breakdowns and analytics for Firefly Neuro (AIFF)
- stock price and consensus target price:
- market capitalization indicators:
- book value of equity indicators:
- company total debt and liquidity indicators:
Debt to Equity Firefly Neuroscience, Inc|AIFF - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Firefly Neuroscience, Inc|AIFF - Company Cumulative Debt|Debt to Book Capitalization Ratio AIFF|AIFF - Long-Term Debt Volume|Company Short-Term Debts Firefly Neuroscience|Quick Ratio fireflyneuro.com
- financial results and valuation multiples details:
AIFF - Net Financial Result|Projected Future Earnings Firefly Neuroscience, Inc|AIFF - Market Cap to Earnings|Future Price to Earnings Firefly Neuroscience Inc|AIFF - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple AIFF|AIFF - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Firefly Neuroscience|AIFF - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months fireflyneuro.com|AIFF - Earnings per share increase in current year|Earnings growth forecast for next year Firefly Neuroscience, Inc
- revenue and sales details:
Initial company analysis:AIFF (Firefly Neuroscience)
To identify fundamental leaders, the analyst evaluates the ratio of market capitalization to expected annual revenue, which determines the premium paid for future growth. The projected P/S metric reflects market expectations for the commercialization of AI-driven brain activity diagnostics by Firefly Neuroscience, Inc (AIFF), helping investors align the share price with the potential for integrating objective neurobiological data into clinical practice.
Analysis of competing companies
Biogen - Forward Price-to-Revenue Multiple|Forward Price to Sales NBIX|RGC - Price-to-Projected Revenue Ratio|AXSM (Axsome Corp) - Market Cap to Projected Revenue|ACAD: Forward P/S Multiple|Market Cap to Future Revenue Ratio xenon-pharma.com (XENE)|Forward Price-to-Revenue Multiple VKTX|Forward P/S Multiple Supernus Pharmaceuticals, Inc.|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|DNLI (Denali Corp) - Forward Price to Sales|Price-to-Projected Revenue Ratio Harmony Biosciences HRMY|biohavenpharma.com (BHVN) - Market Cap to Future Revenue Ratio|AMLX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Trevi Therapeutics Inc TRVI|PRAX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Anavex Life Sciences Corp|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Prothena Corporation (PRTA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALEC|ANNX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Omeros OMER|NGNE: Market Cap to Projected Revenue|AC Immune - Forward P/S Multiple|voyagertherapeutics.com (VYGR) - Forward Price-to-Revenue Multiple|NMRA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Scilex Holding (SCLX)|Forward Price-to-Revenue Multiple TVGN|ACOG: Forward Price to Sales|Forward P/S Multiple CGTX|Market Cap to Expected Sales Ratio inhibikase.com|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|ASRT: Market Cap to Projected Revenue|Coya - Forward P/S Multiple|Vistagen Therapeutics (VTGN) - Forward Price-to-Revenue Multiple|OVID: Forward P/S Multiple|acumenpharm.com (ABOS) - Forward P/S Multiple|CRVO (CervoMed) - Forward P/S Multiple|Alterity Therapeutics Ltd (ATHE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple CLNN|PEPG: Future Price to Revenue|Forward P/S Multiple JUNS (Jupiter Neurosciences Inc)|RLMD (relmada.com) - Future Price to Revenue|ANVS - Price-to-Projected Revenue Ratio|GRCE (Grace Therapeutics, Inc.) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|Market Cap to Future Revenue Ratio NeuroSense Therapeutics Ltd. (NRSN)|Forward Price-to-Revenue Multiple RVPH|Forward P/S Multiple MetaVia, Inc.|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|HSDT (heliusmedical.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Market Cap to Future Revenue Ratio|Minerva Neurosciences - Forward P/S Multiple|Future Price to Revenue ATHA|ADXN: Forward P/S Multiple|ALZN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|PTIX: Forward Price to Sales|Forward P/S Multiple KTTA|CRGT - Market Cap to Future Revenue Ratio|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|BCLI (Brainstorm Cell Therapeutics Inc.) - Future Price to Revenue|CARA - Price-to-Projected Revenue Ratio|CHRO: Price-to-Projected Revenue Ratio|ELYM (eliemtx.com) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|Forward Price-to-Revenue Multiple LBPH|MRNS: Forward Price to Sales|Price-to-Projected Revenue Ratio NKGen (NKGN)|NeuroBo Pharma - Market Cap to Projected Revenue|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|synaptogen.com (SNPX) - Market Cap to Future Revenue Ratio|TRVN: Forward Price-to-Revenue Multiple|VIGL - Forward P/S Multiple|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|Cerevel Corp - Forward Price to Sales
